Successful renal transplantation in Muckle-Wells syndrome treated with anti-IL-1β-monoclonal antibody.

We report the first case of a 32-year-old woman with Muckle-Wells syndrome and biopsy-proven systemic AA amyloidosis and end-stage renal disease. She was treated with canakinumab 150 mg subcutaneously every 8 weeks and underwent renal transplantation. Fourteen months after renal transplanation, the patient had no flares of Muckle-Wells syndrome and no evidence of amyloidosis in the renal transplant under an excellent graft function and therapy with canakinumab.